Molbio Diagnostics IPO opened for subscription today, witnessing an overall subscription of 0.81x on Day 1. The Qualified Institutional Buyers (QIB) category led the demand with a 1x subscription, while the Non-Institutional Individual (NII) and Retail categories saw lower participation.

Subscription Status

On the first day of the issue, the subscription numbers were as follows:

About the Company

Molbio Diagnostics is a prominent player in the diagnostics sector. The company has filed its IPO to raise capital through this public offering. Key financial metrics and operational details are outlined in the prospectus filed with regulatory authorities.

Offer Details

The issue is priced between ₹768 and ₹807 per share. The minimum bid quantity is set at 18 shares. The IPO size ranges from ₹13,158 crore to ₹5,00,000 crore as per the provided data parameters.

Molbio Diagnostics Limited, a leader in point-of-care (POC) molecular diagnostics, has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI). The company, headquartered in Verna, South Goa, operates the proprietary 'Truenat' platform, which delivers accurate diagnostic results within approximately 60 minutes using portable, battery-operated PCR technology. The proposed IPO involves a fresh issue of ₹177.81 crore, aimed at funding significant capital expenditure for R&D consolidation and manufacturing automation. With the IPO scheduled to open on 10-Aug-2026, investors are closely monitoring the financial performance and risk factors outlined in the filing.

Company Overview

Molbio Diagnostics was founded in 2000 and specializes in developing accurate, rapid, and cost-effective healthcare technologies for diagnosing infectious and non-communicable diseases. Its flagship product, the Truenat platform, comprises the Trueprep nucleic acid extraction device and the Truelab Analyzer. As of March 31, 2026, the platform supports 43 assays for 30 diseases, including tuberculosis, COVID-19, Hepatitis B & C, HIV, and HPV.

The company operates in an oligopolistic market with high entry barriers, having required 13 years of R&D to obtain ICMR certification. Molbio holds a strong position in tuberculosis diagnostics, which constituted 70.20% of FY2026 revenues. The global Point-of-Care Testing (POCT) market is valued at USD 29.3 billion and projected to reach USD 67.1 billion by 2030, growing at a CAGR of 17.9% between 2025–2030.

Key management includes CEO Sriram Natarajan (35 years experience) and CTO Dr. Chandrasekhar Bhaskaran Nair (34 years experience). Recent strategic acquisitions include a 65.47% stake in Prognosys Medical Systems (March 2023) for radiology capabilities and a 60.00% stake in OptraScan INC (October 2024) for digital pathology solutions.

Offer Details

The IPO structure consists solely of a fresh issue, with no Offer for Sale (OFS) component disclosed in the DRHP data provided. The total identified capital expenditure from the proceeds is ₹177.81 crore.

Objects of the Issue

The proceeds will be utilized for the following purposes:

1. R&D Facility and Center of Excellence: ₹105.53 crore for a ~150,000 sq. ft. built-up area to consolidate R&D functions operated by wholly-owned subsidiary Bigtec.
2. Manufacturing Capex: ₹72.28 crore for purchase of plant, machinery, and equipment (including automatic precision liquid micro-volume filling machines) for Goa Unit I, Goa Unit II, and Visakhapatnam Unit.
3. General Corporate Purposes: Amount not specified, subject to not exceeding 25% of Gross Proceeds.

IPO Timeline

Price band, lot size, and reservation categories are not available in the current DRHP data.

Financial Highlights

Molbio Diagnostics has demonstrated strong revenue growth over the past three years. Revenue from operations grew at a CAGR of ~31.36% from ₹836.56 crore in FY2024 to ₹1,445.69 crore in FY2026. Profit After Tax (PAT) grew at a CAGR of ~40.13% over the same period.

Key Financial Metrics (Standalone)

Note: PAT margin contracted from 13.48% in FY2025 to 11.28% in FY2026 despite revenue growth. Operating cash flow declined sharply from ₹287.10 crore in FY2025 to ₹50.39 crore in FY2026.

Risk Factors

Investors should note several material risks highlighted in the DRHP:

1. Heavy Dependence on Government/Aid Agencies: 84.56% of FY2026 revenue was derived from Indian central/state governments and international aid agencies. Policy changes or budget cuts could materially impact revenue.
2. Concentration in TB Diagnostics: Tuberculosis diagnostic test kits contributed 70.20% of FY2026 revenues, creating vulnerability to policy shifts or alternative diagnostic methods.
3. Customer Concentration: Top 10 customers accounted for 83.26% of FY2026 revenues.
4. Working Capital and Debt Risks: Total outstanding borrowings stood at ₹4,225.01 million as of May 31, 2026. Non-current liabilities surged ~436.86% YoY. Working capital days were 166 in FY2026.
5. Subsidiary Losses: Key subsidiaries, including OptraScan INC (losses of ₹111.42 million in FY2026), have incurred losses.
6. Capacity Under-utilization: Truenat Device capacity utilization declined to 42.30% in FY2026 from 58.89% in FY2025.
7. Leasehold Dependencies: All manufacturing facilities, R&D units, and corporate offices are on leased land; no owned property.

Valuation & Peer Comparison

The price band for the IPO has not been disclosed in the DRHP data provided. Therefore, pre-issue P/E, post-issue P/E, and Price-to-Book ratios are not available. Peer comparison data with specific competitor metrics is also not available in the provided text. Investors should evaluate the issue against the FY2026 PAT of ₹164.14 crore and book value of ₹1,308.78 crore once the price band is announced.

Bottom Line

Molbio Diagnostics presents a profile of strong top-line growth and a proprietary technology platform in a high-growth market. However, the DRHP highlights significant concentration risks, particularly regarding government customers and tuberculosis diagnostics. Additionally, rising debt levels, declining operating cash flow, and subsidiary losses warrant careful scrutiny. The final investment decision will depend heavily on the valuation implied by the yet-to-be-announced price band.